{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-079207","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-07-17T20:37:57+00:00","discovered_at":"2026-07-17T20:39:01.271098+00:00","generated_at":"2026-07-17T20:39:07.673211+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CERo Therapeutics enters into $2.085M convertible promissory note with SRX Global","bullets":["Maximum loan amount $2,085,200; $750,000 funded May 23, $663,600 June 23, $671,600 July 14, 2026.","Note bears 10% interest per annum, matures May 28, 2027.","Convertible at lesser of $0.05 or 80% of avg of 5 lowest intraday prices in prior 20 days; 4.99% ownership cap.","Company must file registration statement for resale of shares issuable upon conversion.","Issuance exempt under Section 4(a)(2) and Rule 506(b); Lender is accredited investor."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-079207","json":"https://secwatch.observer/filing/0001213900-26-079207.json","markdown":"https://secwatch.observer/filing/0001213900-26-079207.md","text":"https://secwatch.observer/filing/0001213900-26-079207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026079207/0001213900-26-079207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026079207/ea0298463-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-17T20:39:07.673211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}